CTLA4 and cancer: PD-1 is more extensively expressed on activated cells than CTLA-4 and predominantly modulates effector CTL responses upon interaction with its ligand, programmed death-ligand 1 (PD-L1; B7-H1; CD274) and/or PD-L2 (B7-DC; CD273) on cancer cells (Figure 3B).